UBE2CBP Inhibitors
Chemical inhibitors of UBE2CBP can disrupt its function in the ubiquitination process through various mechanisms of action. E-64, as a cysteine protease inhibitor, can irreversibly bind to the active site of certain proteases, potentially impeding the proteolytic activities that are essential for the ubiquitination pathway in which UBE2CBP participates. This inhibition could prevent the cleavage of peptide bonds, a critical step that precedes the tagging of proteins for degradation. Similarly, MG132 and Lactacystin, both proteasome inhibitors, can lead to the accumulation of polyubiquitinated proteins within the cell. By inhibiting the proteasome's ability to degrade these proteins, they increase the concentration of ubiquitinated substrates, which can saturate UBE2CBP and limit its ability to add ubiquitin to new proteins. Clasto-Lactacystin β-lactone operates in a comparable manner, impeding the proteasome and potentially leading to an excess of substrates that could monopolize UBE2CBP's capacity for further ubiquitination.
ALLN, while primarily a calpain inhibitor, also has the capacity to inhibit the proteasome, thus stabilizing proteins that would otherwise be ubiquitinated and degraded. This effect can indirectly inhibit UBE2CBP by affecting the ubiquitination cycle. Epoxomicin, Velcade (Bortezomib), Carfilzomib, Oprozomib, and MLN9708 (Ixazomib) are all selective proteasome inhibitors that can cause a backlog of ubiquitinated proteins within the cell. This accumulation can effectively restrict UBE2CBP's access to substrates, as the ubiquitination and subsequent degradation process becomes bottlenecked. Finally, Pyr-41 and HBX 41108 target the upstream ubiquitin activation step, with Pyr-41 inhibiting the ubiquitin-activating enzyme E1, and HBX 41108 inhibiting the ubiquitin E1 activating enzyme. By blocking the activation of ubiquitin, these inhibitors can reduce the availability of ubiquitin for UBE2CBP's enzymatic activity, thereby limiting its function in the ubiquitination cascade. Each inhibitor, through its unique mechanism, can influence the efficacy of UBE2CBP in the ubiquitin-proteasome pathway.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
E-64 | 66701-25-5 | sc-201276 sc-201276A sc-201276B | 5 mg 25 mg 250 mg | $275.00 $928.00 $1543.00 | 14 | |
E-64 is a potent, irreversible cysteine protease inhibitor that can inhibit the activity of UBE2CBP by preventing the cleavage of peptide bonds in substrates necessary for ubiquitination processes, which UBE2CBP is involved in. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $56.00 $260.00 $980.00 | 163 | |
MG132 is a proteasome inhibitor that can inhibit the degradation of polyubiquitinated proteins, thus potentially increasing the substrate competition for UBE2CBP and indirectly inhibiting its function in tagging proteins for degradation. | ||||||
Lactacystin | 133343-34-7 | sc-3575 sc-3575A | 200 µg 1 mg | $165.00 $575.00 | 60 | |
Lactacystin is a specific inhibitor of the proteasome that can lead to the accumulation of polyubiquitinated proteins, which could saturate the ubiquitin-proteasome system and indirectly inhibit the function of UBE2CBP by overwhelming its ability to process additional substrates. | ||||||
Epoxomicin | 134381-21-8 | sc-201298C sc-201298 sc-201298A sc-201298B | 50 µg 100 µg 250 µg 500 µg | $134.00 $215.00 $440.00 $496.00 | 19 | |
Epoxomicin is a selective proteasome inhibitor that can lead to the build-up of ubiquitinated proteins, potentially indirectly inhibiting UBE2CBP activity by reducing its ability to ubiquitinate new substrates due to the accumulation of already ubiquitinated proteins. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
Bortezomib is a well-known proteasome inhibitor that can lead to the accumulation of polyubiquitinated proteins, potentially inhibiting the activity of UBE2CBP indirectly by limiting its access to substrates for ubiquitination due to the competition with the already ubiquitinated and accumulated proteins. | ||||||
Carfilzomib | 868540-17-4 | sc-396755 | 5 mg | $40.00 | ||
Carfilzomib is another proteasome inhibitor that can cause the accumulation of polyubiquitinated proteins, potentially indirectly inhibiting the ubiquitination function of UBE2CBP by increasing the levels of substrates already bound with ubiquitin and thus limiting the pool of available substrates for ubiquitination by UBE2CBP. | ||||||
Oprozomib | 935888-69-0 | sc-477447 | 2.5 mg | $280.00 | ||
Oprozomib is an orally bioavailable proteasome inhibitor that can inhibit the degradation of polyubiquitinated proteins, potentially causing an indirect inhibition of UBE2CBP by leading to a saturation of the proteasome pathway and limiting the ubiquitination process that UBE2CBP is involved in. | ||||||
Ixazomib | 1072833-77-2 | sc-489103 sc-489103A | 10 mg 50 mg | $311.00 $719.00 | ||
Ixazomib is a proteasome inhibitor that can lead to the accumulation of polyubiquitinated proteins, indirectly inhibiting the function of UBE2CBP by causing a backlog in the proteasome pathway, which could reduce the efficiency of UBE2CBP-mediated ubiquitination of new substrates. | ||||||
Ubiquitin E1 Inhibitor, PYR-41 | 418805-02-4 | sc-358737 | 25 mg | $360.00 | 4 | |
Pyr-41 is a ubiquitin-activating enzyme E1 inhibitor, which can indirectly inhibit UBE2CBP by preventing the initial step of ubiquitin activation, thus reducing the ubiquitin conjugation that UBE2CBP would normally perform. | ||||||